EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Delta

Ensembl ID : ENSUMAG00000010355
Gene Symbol: GABRD
4 Cross references
193 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Epsilon

Ensembl ID : ENSUMAG00000020438
Gene Symbol: GABRE
4 Cross references
109 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2

Ensembl ID : ENSUMAG00000024810
Gene Symbol: GABRG2
4 Cross references
207 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Pi

Ensembl ID : ENSUMAG00000024666
Gene Symbol: GABRP
4 Cross references
124 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Theta

Ensembl ID : ENSUMAG00000021794
Gene Symbol: GABRQ
4 Cross references
87 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSUMAG00000019084
Gene Symbol: GABBR1
4 Cross references
264 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 2

Ensembl ID : ENSUMAG00000012438
Gene Symbol: GABBR2
4 Cross references
241 Possible Orthologues:

Gastric Inhibitory Polypeptide Receptor

Ensembl ID : ENSUMAG00000023684
Gene Symbol: GIPR
4 Cross references
93 Possible Orthologues:

Glucagon Like Peptide 1 Receptor

Ensembl ID : ENSUMAG00000005496
Gene Symbol: GLP1R
4 Cross references
133 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSUMAG00000017848
Gene Symbol: GLP2R
2 Cross references
205 Possible Orthologues:

Glucosylceramidase Beta 1

Ensembl ID : ENSUMAG00000019554
Gene Symbol: GBA1
4 Cross references
254 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 1

Ensembl ID : ENSUMAG00000003146
Gene Symbol: GRIA1
4 Cross references
323 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).